{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"284"}],"title":"Never-positive"},{"measurements":[{"groupId":"OG000","value":"60"}],"title":"Ever-positive"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"344"}],"units":"Participants"}],"description":"nAb against avelumab in serum samples was determined and reported separately for nAb never positive and nAb ever positive participants. Participants were considered nAb ever-positive if they had at least one positive nAb result at any time point during study and were otherwise considered negative.","groups":[{"description":"Participants received an intravenous (IV) infusion of 10 milligrams per kilograms (mg/kg) of Avelumab along with BSC, on Day 1 and 15 of each 28 days treatment cycle, until confirmed disease progression, participant refusal, lost to follow up, unacceptable toxicity, or study termination by the sponsor, whichever occurred first. BSC was administered as per the treating physician. Participants were followed up until death, end of the study or withdrawal of consent, whichever comes first, regardless of initiation of new anti-cancer therapy.","id":"OG000","title":"Avelumab + Best Supportive Care (BSC)"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"The immunogenicity analysis set included all participants who had received at least one dose of study drug and who had at least one nAb sample collected for avelumab in the avelumab containing arm.","reportingStatus":"POSTED","timeFrame":"From randomization up to the 30-Day Follow-up visit (maximum duration of up to approximately 68 months)","title":"Number of Participants With Neutralizing Antibodies (nAb) Against Avelumab by Never Positive and Ever Positive Status","type":"SECONDARY","unitOfMeasure":"Participants"}